China will receive cut-price supplies of GlaxoSmithKline's new HIV drug Tivicay, following a deal for Shanghai-based Desano Pharmaceuticals to become an additional manufacturer of the medicine's active ingredient. The collaboration between GSK's HIV unit ViiV Healthcare and Desano marks an improvement in the business climate for the British drugmaker, which was fined a record 3 billion yuan in September for bribing Chinese doctors.